Precision BioSciences has received US patent which covers claims related to methods of cleaving a target DNA site in a cell using an engineered meganuclease. These methods are broadly utilized as a part of Precision’s DNE genome engineering technology, the company said. Precision announced in October 2011 that it has asserted the ‘867 Patent against Cellectis in a suit pending in the US District Court for the Eastern District of North Carolina.
Precision scientific development vice president said the claimed methods include the use of engineered features that are a key aspect of Precision’s award-winning DNE approach to genome engineering.
